This Medudy course is a video tutorial for physicians on the topic “HER2 Diagnostics as the Key to Targeted Therapy Decisions.”
In this video, Professor Markus Eckstein, senior physician at the Institute of Pathology at Erlangen University Hospital, explains the relationship between HER2 diagnostics and the use of targeted therapies for various solid tumors. Generally, three therapeutically relevant alterations are distinguished: HER2 protein overexpression, HER2 gene amplification, and activating HER2 gene mutations. The diagnostic procedure depends on the specific alteration being detected. Since clinically significant benefits have been demonstrated in various tumor types, accurate determination of HER2 status is particularly important for HER2-overexpressing tumors. For this purpose, tumors are classified as IHC 0 to IHC 3+ according to the more inclusive scoring criteria validated for gastric carcinomas.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. The video content was created and reviewed by the editorial team with the aid of AI, based on high-quality scientific sources, and has been approved by the speakers.
This course was made possible with the generous support of AstraZeneca.
At the end of this training you will know:
- the basic biological properties of the HER2 receptor
- therapeutically relevant HER2 alterations and the associated diagnostic procedures
- Criteria for Classifying HER2 IHC Status
- The Role of HER2 Diagnostics in Modern Oncology
